CytomX Therapeutics Inc (CTMX)vsBeiGene, Ltd. (ONC)

CTMX

CytomX Therapeutics Inc

NASDAQ

$4.24

-4.93%

HEALTHCARE · Cap: $757.33M

ONC

BeiGene, Ltd.

NASDAQ

$283.45

+2.81%

HEALTHCARE · Cap: $31.62B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

BeiGene, Ltd. generates 6912% more annual revenue ($5.34B vs $76.20M). ONC leads profitability with a 5.4% profit margin vs -22.8%. ONC earns a higher WallStSmart Score of 42/100 (D).

CTMX

Avoid

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 5.0

ONC

Hold

out of 100

Grade: D

Growth: 8.0Profit: 5.0Value: 3.0Quality: 6.5

Piotroski: 5/9Altman Z: 0.26

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CTMX.

ONCSignificantly Overvalued (-1983.5%)

Margin of Safety

-1983.5%

Fair Value

$16.86

Current Price

$283.45

$266.59 premium

UndervaluedFair: $16.86Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTMX1 strengths · Avg: 10.0/10

EPS GrowthGrowth

60.6%10/10

Earnings expanding 60.6% YoY

ONC2 strengths · Avg: 9.5/10

Revenue GrowthGrowth

32.8%10/10

Revenue surging 32.8% year-over-year

Debt/EquityHealth

0.259/10

Conservative balance sheet, low leverage

Areas to Watch

CTMX4 concerns · Avg: 2.3/10

Market CapQuality

$757.33M3/10

Smaller company, higher risk/reward

Return on EquityProfitability

-35.2%2/10

ROE of -35.2% — below average capital efficiency

Revenue GrowthGrowth

-98.3%2/10

Revenue declined 98.3%

Free Cash FlowQuality

$-23.44M2/10

Negative free cash flow — burning cash

ONC4 concerns · Avg: 3.0/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Return on EquityProfitability

7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability

5.4%3/10

5.4% margin — thin

P/E RatioValuation

111.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : CTMX

The strongest argument for CTMX centers on EPS Growth.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.

Bear Case : CTMX

The primary concerns for CTMX are Market Cap, Return on Equity, Revenue Growth.

Bear Case : ONC

The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.

Key Dynamics to Monitor

CTMX profiles as a turnaround stock while ONC is a hypergrowth play — different risk/reward profiles.

CTMX carries more volatility with a beta of 2.48 — expect wider price swings.

ONC is growing revenue faster at 32.8% — sustainability is the question.

ONC generates stronger free cash flow (131M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (42/100 vs 26/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CytomX Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Compare with Other BIOTECHNOLOGY Stocks

CTMX vs VRTX CTMX vs REGN CTMX vs ARGX CTMX vs ALNY CTMX vs INSM ONC vs VRTX ONC vs REGN ONC vs ARGX ONC vs ALNY ONC vs INSM

Want to dig deeper into these stocks?

Full CTMX Analysis →Full ONC Analysis →